VRDN vs RDVT

For growth investors, Viridian Therapeutics, Inc.

(VRDN) is the stronger pick with 233. 6% revenue growth year-over-year, versus 20. 0% for Red Violet, Inc. (RDVT). Red Violet, Inc. (RDVT) offers the better valuation at 53. 9x trailing P/E (36. 5x forward), making it the more compelling value choice. Analysts rate Viridian Therapeutics, Inc. (VRDN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Red Violet, Inc.

(RDVT) delivered a total return of +155. 9%, compared to -3. 2% for Viridian Therapeutics, Inc. (VRDN). Over 10 years, the gap is even starker: RDVT returned +6. 4% versus VRDN's -87. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Red Violet, Inc.

(RDVT) is the lower-risk stock at 1. 17β versus Viridian Therapeutics, Inc. 's 1. 24β — meaning VRDN is approximately 6% more volatile than RDVT relative to the S&P 500. On balance sheet safety, Red Violet, Inc. (RDVT) carries a lower debt/equity ratio of 3% versus 7% for Viridian Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Viridian Therapeutics, Inc.

(VRDN) is pulling ahead at 233. 6% versus 20. 0% for Red Violet, Inc. (RDVT). On earnings-per-share growth, the picture is similar: Red Violet, Inc. grew EPS 82. 0% year-over-year, compared to 16. 6% for Viridian Therapeutics, Inc.. Over a 3-year CAGR, VRDN leads at 241. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Red Violet, Inc.

(RDVT) is the more profitable company, earning 14. 6% net margin versus -483. 6% for Viridian Therapeutics, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDVT leads at 14. 6% versus -512. 9% for VRDN. At the gross margin level — before operating expenses — VRDN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for VRDN: 151.

4% to $42. 67.

In this comparison, RDVT (0.

6% yield) pays a dividend. VRDN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Red Violet, Inc.

(RDVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), 0. 6% yield). Both have compounded well over 10 years (RDVT: +6. 4%, VRDN: -87. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VRDN (Healthcare) and RDVT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

RDVT pays a dividend while VRDN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.